{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:53:09Z","timestamp":1776433989710,"version":"3.51.2"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jbo.2021.100405","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T10:03:39Z","timestamp":1638093819000},"page":"100405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Bone metastases from urothelial carcinoma. The dark side of the moon"],"prefix":"10.1016","volume":"31","author":[{"given":"Marco","family":"Stellato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Foderaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2021.100405_b0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.jbo.2021.100405_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.jbo.2021.100405_b0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2021.100405_b0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bju.12601","article-title":"Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base","volume":"114","author":"Smith","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2021.100405_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.jbo.2021.100405_b0030","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci. (Basel, Switzerland)"},{"key":"10.1016\/j.jbo.2021.100405_b0035","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2021.100405_b0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000489218","article-title":"Clinical features and risk factors of skeletal-related events in genitourinary cancer patients with bone metastasis: a retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma","volume":"95","author":"Owari","year":"2018","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.jbo.2021.100405_b0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0090-4295(80)90067-9","article-title":"Metastases from transitional cell carcinoma of urinary bladder","volume":"16","author":"Babaian","year":"1980","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2021.100405_b0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2214\/ajr.132.3.419","article-title":"Metastatic transitional cell carcinoma from the bladder: radiographic manifestions","volume":"132","author":"Goldman","year":"1979","journal-title":"AJR. Am. J. Roentgenol."},{"issue":"24","key":"10.1016\/j.jbo.2021.100405_b0055","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.7150\/jca.28706","article-title":"Bone metastases pattern in newly diagnosed metastatic bladder cancer: a population-based study","volume":"9","author":"Zhang","year":"2018","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2021.100405_b0060","doi-asserted-by":"crossref","first-page":"e0183835","DOI":"10.1371\/journal.pone.0183835","article-title":"Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jbo.2021.100405_b0065","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022675","article-title":"Risk factors and nomogram for newly diagnosis of bone metastasis in bladder cancer: a SEER-based study","volume":"99","author":"Fan","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.jbo.2021.100405_b0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CMAR.S148856","article-title":"Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study","volume":"9","author":"Dong","year":"2017","journal-title":"Cancer Manage. Res."},{"issue":"1","key":"10.1016\/j.jbo.2021.100405_b0075","doi-asserted-by":"crossref","first-page":"74.e9","DOI":"10.1016\/j.urolonc.2020.09.029","article-title":"Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma","volume":"39","author":"Cheaib","year":"2021","journal-title":"Urol. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2021.100405_b0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10585-018-9884-z","article-title":"How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data","volume":"34","author":"Dong","year":"2017","journal-title":"Clin. & Exp. Metastasis"},{"key":"10.1016\/j.jbo.2021.100405_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-5347(01)66562-5","article-title":"Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma","volume":"155","author":"Sengel\u00f8v","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.jbo.2021.100405_b0090","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10147-016-1075-9","article-title":"Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis","volume":"22","author":"Tsuda","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2021.100405_b0095","doi-asserted-by":"crossref","first-page":"495.e9","DOI":"10.1016\/j.urolonc.2015.07.001","article-title":"The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy","volume":"33","author":"Hsieh","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jbo.2021.100405_b0100","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1016\/j.clgc.2017.10.012","article-title":"Bone metastases as the only metastatic site in patients with urothelial carcinoma: focus on a special patient population","volume":"16","author":"Necchi","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.jbo.2021.100405_b0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jb\/mvp148","article-title":"Bone morphogenetic protein receptors and signal transduction","volume":"147","author":"Miyazono","year":"2010","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbo.2021.100405_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.anndiagpath.2012.05.008","article-title":"Expression of bone-morphogenetic protein 2 and tumor necrosis factor \u03b1 correlates with bone metastases in bladder urothelial carcinoma","volume":"17","author":"Yang","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.jbo.2021.100405_b0115","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","article-title":"Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism","volume":"65","author":"Dai","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2021.100405_b0120","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1074\/jbc.M609484200","article-title":"Med19(Rox3) regulates Intermodule interactions in the Saccharomyces cerevisiae mediator complex","volume":"282","author":"Baidoobonso","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jbo.2021.100405_b0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(94)90221-6","article-title":"A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II","volume":"77","author":"Kim","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jbo.2021.100405_b0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anndiagpath.2012.11.004","article-title":"Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2","volume":"17","author":"Wen","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.jbo.2021.100405_b0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euf.2019.06.007","article-title":"Systemic treatment of bone disease in metastatic urinary malignancies","volume":"6","author":"Patel","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.jbo.2021.100405_b0140","series-title":"Linee guida Aiom \u2013 Trattamento delle metastasi ossee","author":"Santini","year":"2018"},{"key":"10.1016\/j.jbo.2021.100405_b0145","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07- 3.o Title, n.d."},{"key":"10.1016\/j.jbo.2021.100405_b0150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100405_b0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100405_b0160","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100405_b0165","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1442-2042.2010.02468.x","article-title":"Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan","volume":"17","author":"Yokomizo","year":"2010","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.jbo.2021.100405_b0170","doi-asserted-by":"crossref","unstructured":"S. Baleato-Gonz\u00e1lez, R. Garc\u00eda-Figueiras, Specific criteria for tumor response., Radiologia. 60 Suppl 1 (2018) 64\u201381. https:\/\/doi.org\/10.1016\/j.rx.2018.01.005.","DOI":"10.1016\/j.rx.2018.01.005"},{"key":"10.1016\/j.jbo.2021.100405_b0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2021.100405_b0180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10122","key":"10.1016\/j.jbo.2021.100405_b0185","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jbo.2021.100405_b0190","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-779","article-title":"Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice","volume":"14","author":"Castellano","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2021.100405_b0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100405_b0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.eururo.2019.10.004","article-title":"Clinical outcome after progressing to frontline and second-line Anti-PD-1\/PD-L1 in advanced urothelial cancer.: european urology","volume":"77","author":"de Lia\u00f1o","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2021.100405_b0205","doi-asserted-by":"crossref","unstructured":"S.T. Tagawa D.P. Petrylak P. Grivas N. Agarwal C.N. Sternberg C. Hernandez P. Siemon-Hryczyk T. Goswami Y. Loriot TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and\/or anti-PD-1\/PD-L1 checkpoint inhibitor therapy J. Clin. Oncol. 37 15_suppl 2019 TPS3153 TPS3153.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3153"},{"key":"10.1016\/j.jbo.2021.100405_b0210","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jbo.2021.100405_b0215","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100405_b0220","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","article-title":"Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial","volume":"21","author":"Apolo","year":"2020","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.jbo.2021.100405_b0225","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2021.100405_b0230","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer[Formula presented]","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:20:54Z","timestamp":1761942054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137421000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":46,"alternative-id":["S2212137421000609"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100405","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone metastases from urothelial carcinoma. The dark side of the moon","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100405"}}